Condition (MeSH)
Gingival Neoplasms
ClinicalTrials.gov lists 1 trial for Gingival Neoplasms or a narrower condition beneath it. Vigilant Biosciences, Inc. has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section
3 sections measured, none recorded · 1 not measured yet · 1 not computed
1 of the 1 trial is tagged with Gingival Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Gingival Neoplasms trials start? (1)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2017 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 1 trial evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Gingival Neoplasms trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 1 |
How many Gingival Neoplasms trials are recruiting? (1)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Gingival Neoplasms trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Vigilant Biosciences, Inc. | 1 |
Which publications cover Gingival Neoplasms? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A large-cohort study of 2971 cases of epulis: focusing on risk factors associated with recurrence. | BMC oral health | 2023 | Yes |
| Gingival involvement in a case series of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. | Journal of periodontology | 2006 | Yes |
| Peripheral ameloblastoma of the gingiva. A case report. | Journal of periodontology | 1990 | Yes |
| Detecting early oral cancer: narrowband imaging system observation of the oral mucosa microvasculature. | International journal of oral and maxillofacial surgery | 2010 | No |
| Benefits of dental implants installed during ablative tumour surgery in oral cancer patients: a prospective 5-year clinical trial. | Clinical oral implants research | 2010 | No |
Showing 5 of 8 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Congenital epulis | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.